Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas

Marco Losa, Pietro Mortini, Angela Pagnano, Mario Detomas, Maria Francesca Cassarino, Francesca Pecori Giraldi

Research output: Contribution to journalArticle

Abstract

Purpose: somatic mutations in the ubiquitin-specific protease 8 (USP8) gene have recently been described in patients with Cushing’s disease (CD). The aim of the study is to verify whether USP8 mutation may predict early and late outcome of pituitary surgery in patients with CD operated at a single institution. Methods: We performed a retrospective genetic analysis of 92 adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas. Specimens were screened for USP8 hotspot mutations in the exon 14 with Sanger sequencing. Hormonal and surgical data were compared between USP8 variant carriers and wild-type tumors. Results: USP8 variants were detected in 22 adenomas (23.9%) with higher prevalence in women (28.9% vs. 5.3% in men; p < 0.05). No significant difference in hormonal levels and tumoral features in relation to USP8 status was observed. Interestingly, USP8-variant carriers were more likely to achieve surgical remission than wild-type adenomas (100% vs. 75.7%; p = 0.01). Conversely, recurrence of CD occurred in 23% of USP8-mutated patients and in 13% of patients with wild-type adenoma. The recurrence-free survival did not differ significantly between the two groups (p = 0.42). Conclusions: ACTH-secreting pituitary adenomas carrying somatic USP8 mutations are associated with a greater likelihood of surgical remission in patients operated by a single neurosurgeon. Recurrence rates are not related with USP8-variant status.

Original languageEnglish
Pages (from-to)240-246
Number of pages7
JournalEndocrine
Volume63
Issue number2
DOIs
Publication statusPublished - Feb 15 2019

Fingerprint

Ubiquitin-Specific Proteases
Pituitary Neoplasms
Adrenocorticotropic Hormone
Pituitary ACTH Hypersecretion
Adenoma
Mutation
Recurrence
Exons

Keywords

  • Adrenocorticotropin
  • Cortisol
  • Pituitary neoplasms
  • Pituitary surgery

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas. / Losa, Marco; Mortini, Pietro; Pagnano, Angela; Detomas, Mario; Cassarino, Maria Francesca; Pecori Giraldi, Francesca.

In: Endocrine, Vol. 63, No. 2, 15.02.2019, p. 240-246.

Research output: Contribution to journalArticle

@article{593cb36a5c89492ea5f1cb08e495d5c3,
title = "Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas",
abstract = "Purpose: somatic mutations in the ubiquitin-specific protease 8 (USP8) gene have recently been described in patients with Cushing’s disease (CD). The aim of the study is to verify whether USP8 mutation may predict early and late outcome of pituitary surgery in patients with CD operated at a single institution. Methods: We performed a retrospective genetic analysis of 92 adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas. Specimens were screened for USP8 hotspot mutations in the exon 14 with Sanger sequencing. Hormonal and surgical data were compared between USP8 variant carriers and wild-type tumors. Results: USP8 variants were detected in 22 adenomas (23.9{\%}) with higher prevalence in women (28.9{\%} vs. 5.3{\%} in men; p < 0.05). No significant difference in hormonal levels and tumoral features in relation to USP8 status was observed. Interestingly, USP8-variant carriers were more likely to achieve surgical remission than wild-type adenomas (100{\%} vs. 75.7{\%}; p = 0.01). Conversely, recurrence of CD occurred in 23{\%} of USP8-mutated patients and in 13{\%} of patients with wild-type adenoma. The recurrence-free survival did not differ significantly between the two groups (p = 0.42). Conclusions: ACTH-secreting pituitary adenomas carrying somatic USP8 mutations are associated with a greater likelihood of surgical remission in patients operated by a single neurosurgeon. Recurrence rates are not related with USP8-variant status.",
keywords = "Adrenocorticotropin, Cortisol, Pituitary neoplasms, Pituitary surgery",
author = "Marco Losa and Pietro Mortini and Angela Pagnano and Mario Detomas and Cassarino, {Maria Francesca} and {Pecori Giraldi}, Francesca",
year = "2019",
month = "2",
day = "15",
doi = "10.1007/s12020-018-1776-0",
language = "English",
volume = "63",
pages = "240--246",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas

AU - Losa, Marco

AU - Mortini, Pietro

AU - Pagnano, Angela

AU - Detomas, Mario

AU - Cassarino, Maria Francesca

AU - Pecori Giraldi, Francesca

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Purpose: somatic mutations in the ubiquitin-specific protease 8 (USP8) gene have recently been described in patients with Cushing’s disease (CD). The aim of the study is to verify whether USP8 mutation may predict early and late outcome of pituitary surgery in patients with CD operated at a single institution. Methods: We performed a retrospective genetic analysis of 92 adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas. Specimens were screened for USP8 hotspot mutations in the exon 14 with Sanger sequencing. Hormonal and surgical data were compared between USP8 variant carriers and wild-type tumors. Results: USP8 variants were detected in 22 adenomas (23.9%) with higher prevalence in women (28.9% vs. 5.3% in men; p < 0.05). No significant difference in hormonal levels and tumoral features in relation to USP8 status was observed. Interestingly, USP8-variant carriers were more likely to achieve surgical remission than wild-type adenomas (100% vs. 75.7%; p = 0.01). Conversely, recurrence of CD occurred in 23% of USP8-mutated patients and in 13% of patients with wild-type adenoma. The recurrence-free survival did not differ significantly between the two groups (p = 0.42). Conclusions: ACTH-secreting pituitary adenomas carrying somatic USP8 mutations are associated with a greater likelihood of surgical remission in patients operated by a single neurosurgeon. Recurrence rates are not related with USP8-variant status.

AB - Purpose: somatic mutations in the ubiquitin-specific protease 8 (USP8) gene have recently been described in patients with Cushing’s disease (CD). The aim of the study is to verify whether USP8 mutation may predict early and late outcome of pituitary surgery in patients with CD operated at a single institution. Methods: We performed a retrospective genetic analysis of 92 adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas. Specimens were screened for USP8 hotspot mutations in the exon 14 with Sanger sequencing. Hormonal and surgical data were compared between USP8 variant carriers and wild-type tumors. Results: USP8 variants were detected in 22 adenomas (23.9%) with higher prevalence in women (28.9% vs. 5.3% in men; p < 0.05). No significant difference in hormonal levels and tumoral features in relation to USP8 status was observed. Interestingly, USP8-variant carriers were more likely to achieve surgical remission than wild-type adenomas (100% vs. 75.7%; p = 0.01). Conversely, recurrence of CD occurred in 23% of USP8-mutated patients and in 13% of patients with wild-type adenoma. The recurrence-free survival did not differ significantly between the two groups (p = 0.42). Conclusions: ACTH-secreting pituitary adenomas carrying somatic USP8 mutations are associated with a greater likelihood of surgical remission in patients operated by a single neurosurgeon. Recurrence rates are not related with USP8-variant status.

KW - Adrenocorticotropin

KW - Cortisol

KW - Pituitary neoplasms

KW - Pituitary surgery

UR - http://www.scopus.com/inward/record.url?scp=85055474306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055474306&partnerID=8YFLogxK

U2 - 10.1007/s12020-018-1776-0

DO - 10.1007/s12020-018-1776-0

M3 - Article

C2 - 30315484

AN - SCOPUS:85055474306

VL - 63

SP - 240

EP - 246

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 2

ER -